Company: SION
Filing Date: 2025-01-17
Form Type: S-1
Source: 0001193125-25-008474
Chunk: 121

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-01-17
Form: S-1
Chunk 121
---
 a public company.                                      |

We may also use a portion of the remaining net proceeds and our existing cash, cash equivalents and investments in marketable securities to in-license,acquire or invest in complementary businesses, technologies, products or assets. However, we have no current commitments, agreements, understandings or obligations to do so. We believe, based on our current operating plan, that the net proceeds from this offering, together with our existing cash, cash equivalents and investments in marketable securities, will be sufficient to fund our operations through . Our expected use of proceeds from this offering described above represents our current intentions based on our present plans and business condition. As of the date of this prospectus, we 85

cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the actual amounts that we will spend on the uses set forth
above. We expect that we will require additional funds in order to fully accomplish the specified uses of the proceeds of this offering. Moreover, certain of our anticipated clinical activities are cross-program. For example, we intend to conduct
dual combination trials of our lead NBD1 stabilizer with one or more of our complementary modulators. The specific allocation and timing of our actual expenditures will depend on numerous factors, including progress of our research and development
efforts, the status of and results from preclinical studies and ongoing and future clinical trials, the timing and outcome of regulatory submissions, and other factors described in “Risk Factors” in this prospectus, as well as the
amount of cash used in our operations and any unforeseen cash needs. Therefore, our actual expenditures may differ materially from the estimates described above. We may find it necessary or advisable to use the net proceeds for other purposes.

We will have broad discretion over how to use the net proceeds to us from this offering and investors will be relying on the judgment of our management
regarding the application of the net proceeds. Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation instruments, including short-term and long-term interest-bearing
instruments, investment-grade securities, and direct or guaranteed obligations of the U.S. government. We cannot predict whether the proceeds invested will yield a favorable return.

86

DIVIDEND POLICY

We have never declared or paid cash dividends on our capital stock. We do not anticipate declaring or paying, in the foreseeable future, any cash
dividends on our capital stock. We intend